Artivion has finalized its acquisition of Endospan Ltd., adding the FDA-approved NEXUS Aortic Arch System to its portfolio of ...
Artivion, Inc. announced that it has completed the acquisition of its long-standing partner Endospan Ltd. On May 8, Artivion announ ...
Medical Device Network on MSN
Artivion strengthens aortic arch portfolio with $135m Endospan acquisition
As per a 2019 deal, Artivion secured the rights to purchase Endospan upon the latter’s US approval of Nexus, a treatment for ...
Endospan, headquartered in Israel, specializes in endovascular technologies designed to treat complex aortic arch disease.
Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to acquire the company. This strategic ...
FDA approval was supported by the one-year results of the TRIOMPHE Investigational Device Exemption (IDE) Study evaluating the NEXUS® System shown to effectively treat aortic arch disease, including ...
PITTSBURGH—University of Pittsburgh-led researchers could provide new insight into how two common congenital circulatory problems—aortic arch deformity and arteriovenous malformations (AVMs)—develop ...
(NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed the acquisition of its long-standing partner Endospan Ltd. ("Endospan"), a ...
ATLANTA, May 18, 2026 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results